Neurotrauma: A Comprehensive Textbook on Traumatic Brain Injury and Spinal Cord Injury

Neurotrauma: A Comprehensive Textbook on Traumatic Brain Injury and Spinal Cord Injury aims to bring together the latest clinical practice and research in the filed of two forms of trauma to the central nervous system: namely traumatic brain injury (TBI) and spinal cord injury (SCI). Nationally, more 1.9 million Americans sustain a traumatic brain injury annually. In parallel, there are an estimate of 12,000 new cases of SCI in the United States annually. In addition, approximately 1.2 million people live with paralysis due to SCI. In recent years, dramatic advancements in the field have resulted in much improved outcomes for patients and higher standards of care. This volume details the latest research and clinical practice in the treatment of neurotrauma, in a comprehensive but easy-to-follow format. Neurotrauma is a valuable resource for any clinician involved in caring for TBI and SCI patients, clinical research professionals, researchers, medical and graduate students, and nurse specialists.

About the Author

Dr. Kevin Wang is the Director of the Program for Neurotrauma, Neuroproteomics&Biomarkers Research and Associate Professor of Emergency Medicine at the University of Florida in Gainesville, Florida, USA. He is also Health Research Neuroscientist and Merit Award Principal Investigator at the Brain Rehabilitation Research Center at the Malcom Randall VA Medical Center (Gainesville, FL). Dr. Wang is a neurotrauma researcher since the late 1990's. He has served as President and Council Member of the National Neurotrauma society, Board Member, Board of Governors of the International Brain Injury Association and Presidium Member of the Academy for Multidisciplinary Neurotraumatology. His research focus is translational research for traumatic brain injury, spinal cord injury, post-traumatic epilepsy, and chronic traumatic encephalopathy. Two acute TBI blood-based protein biomarkers he co-discovered at University of Florida have now been clinically validated. In 2018, these two TBI biomarkers received FDA approval as the first-in class in vitro diagnostic tests for detecting cranial CT abnormality in TBI patients.